Onconetix, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
Onconetix, Inc. (ONCO) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $53.00 thousand for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-12-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2024-12-10
- Onconetix, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2024-09-30 was $53.00K, a 61.31% decline year-over-year.
- Onconetix, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2024-06-30 was $83.00K, a 59.90% decline year-over-year.
- Onconetix, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2024-03-31 was $83.00K, a 69.49% decline year-over-year.
- Onconetix, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2023-12-31 was $84.00K.
- Onconetix, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $700.00K, a 66.67% decline from fiscal 2022.
- Onconetix, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $2.10M, a 2099999900.00% increase from fiscal 2021.
- Onconetix, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2021 was $0.10.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2024-09-30 | $53.00K 10-Q · filed 2024-12-10 | $136.00K derived: sum of 2 quarters · filed 2024-12-10 | $220.00K 10-Q · filed 2024-12-10 | $303.00K derived: sum of 4 quarters · filed 2024-12-10 | |
| 2024-06-30 | $83.00K 10-Q · filed 2024-08-29 | $167.00K 10-Q · filed 2024-08-29 | $250.00K derived: sum of 3 quarters · filed 2024-08-29 | $387.00K derived: sum of 4 quarters · filed 2024-12-10 | |
| 2024-03-31 | $83.00K 10-Q · filed 2024-05-20 | $167.00K derived: sum of 2 quarters · filed 2024-05-20 | $304.00K derived: sum of 3 quarters · filed 2024-12-10 | $511.00K derived: sum of 4 quarters · filed 2024-12-10 | |
| 2023-12-31 | $84.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-11 | $221.00K derived: sum of 2 quarters · filed 2024-12-10 | $428.00K derived: sum of 3 quarters · filed 2024-12-10 | $700.00K 10-K · filed 2024-04-11 | |
| 2023-09-30 | $137.00K 10-Q · filed 2024-12-10 | $344.00K derived: sum of 2 quarters · filed 2024-12-10 | $616.00K 10-Q · filed 2024-12-10 | ||
| 2023-06-30 | $207.00K 10-Q · filed 2024-08-29 | $479.00K 10-Q · filed 2024-08-29 | |||
| 2023-03-31 | $272.00K 10-Q · filed 2024-05-20 | ||||
| 2022-12-31 | $2.10M 10-K · filed 2024-04-11 | $2.10 10-K · filed 2023-03-09 | |||
| 2022-06-30 | $1.13T 10-Q · filed 2022-08-15 | ||||
| 2021-12-31 | $0.10 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |